This trial is evaluating whether SynPhNe platform will improve 3 primary outcomes, 6 secondary outcomes, and 6 other outcomes in patients with Stroke. Measurement will happen over the course of Changes from baseline scores at Baseline, at 7 weeks and at one month follow-up.
This trial requires 40 total participants across 2 different treatment groups
This trial involves 2 different treatments. SynPhNe Platform is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
Stroke may have more than one cause, but cardio-embolic stroke represents 75% of cases. The pathogenesis can be related to atheroma, hypertension and heart failure. Risk factors are age, diabetes, family history (especially first degree relatives). Patients with rheumatic heart disease or mitral stenosis are at higher risk of stroke and should be investigated with echocardiography and cardio-thrombography.
While stroke, particularly transient ischemic attack, remains a leading cause of death globally, it accounts for only 1% of global deaths in the United States. Stroke occurs spontaneously and can occur at any age. In most cases, symptoms of stroke include new focal deficits or a change in the character of a preexisting deficit. Most strokes are due to atrial fibrillation or occlusion of a large blood vessel, typically the anterior cerebral artery. Stroke also is a manifestation of vascular diseases, particularly atherosclerosis. Strokes occur in all regions of the world and every socioeconomic group. Risk factors for stroke include hypertension, diabetes mellitus, and family history of stroke.
Patients who are stroke-free after a car crash should keep a diary of the dates of the car accident and visits to the doctor. In patients with stroke and car accident, car accident should be the first priority. Most strokes that occur in cars are controllable, and the time to reach the hospital or other medical facility should allow treatment to be completed. Patients with stroke and car accident must be seen within 24 hours; and the possibility of other strokes or car accidents in the future could be prevented. Most car crashes occur in the wintertime in the US, and the patient should be taken to a hospital as soon as possible.
A thorough history is essential, including information on symptoms and signs of stroke, such as dizziness, slurred speech, weakness extremities, numbness, aphasia or visual symptoms. There is no one single sign of stroke (stroke-like illness) that is diagnostic. In the event of a suspected stroke, computed tomography, magnetic resonance imaging with and without contrast and diffusion- weighted imaging should be performed if available. An examination of both arms and legs is mandatory, and it includes looking for hemiparesis in the face, arm, finger and leg.
Stroke recovery involves physical, social, occupational and psychological recovery. The most common treatments for stroke are rest and exercise (aerobic training in particular), medication, therapy and counseling and home based service. The goal for stroke rehabilitation is tailored to meet patient's needs and to incorporate the individual's goals and motivation. A multi-disciplinary stroke team is essential to facilitate stroke recovery.
A very small number of patients can be treated by our team and with the available technology. We can not determine the validity of a certain synphne therapy, as there are many possible causes for symptom improvement, and also because synphne is in our opinion a very simplistic approach to the complex and multifaceted processes that occur during stroke recovery. The most promising therapy may be in very specific cases. We’re waiting for further evidence. The most difficult thing to treat is the most difficult stroke.
A randomized controlled trial comparing Synphne to conventional treatment yielded similar results, indicating that Synphne is safe for people treated for minor injuries. The only real difference between Synphne and the control group may be in patients with multiple minor injuries to the upper limb, where the patients did not receive treatment on those sides as this may have led to an increased incidence of post amputation complications. Thus, for people who have sustained multiple minor upper limb injuries to not have their arm supported, this study would suggest that Synphne is a safer alternative to conventional treatment, as it causes no further harm.
An eight-week treatment with Synphne 50 and Synphne 50 + L-Depot with placebo in patients presenting with symptoms of osteoarthritis of the knee did not improve knee function. It was superior to placebo. Synphne 50 and Synphne 50 + L-Depot produced improvements in pain and function.
The present data suggest that the synphne platform is clinically safe for use. The major concerns reported are diarrhea and nasogastric tube placement. It should be remembered that the majority of the patients were in a non-specific (non-serious) state of illness prior to hospital admission, which may not be a true reflection of the actual rate of side effects. The current protocol provides an acceptable level of safety assurance for patients who are hospitalized because they are admitted with new or chronic manifestations of disease.
The predominant cause of stroke in our region is stroke due to atherosclerosis of the cardio cerebral artery. Other factors like hypertension, diabetes, hyperlipoproteinemia and hypercholesterolemia were also prevalent in a small percentage of population. We can control the other risk factors to prevent the occurrence of stroke, therefore, stroke in the region may be prevented.
Data from a recent study have demonstrated that synphne engines display an overall improved fuel economy and carbon dioxide emission at low and medium power output. This implies that synphne can be a suitable design for use in large-scale, real-world vehicle operating environments. We believe our model is the first one developed and implemented to analyse the performance of synphne engines.